Skip to content

Study · Animal study (in vivo) · rat · 2006

1 result

The hypothalamic paraventricular nucleus is not essential for orexigenic NPY or anorexigenic melanocortin action.

Dube MG, Kalra SP, Kalra PS

Peptides8 Jun 2006Cited by 10 (Europe PMC)

PMID16759748 (opens in a new tab)DOI10.1016/j.peptides.2006.04.005 (opens in a new tab)PepBankPUB-16759748
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with paraventricular nucleus lesions, MTII suppressed food intake no differently than in sham-lesioned rats.

    In plain wordsIn rats with hypothalamic lesions, MTII reduced food intake as much as in rats without lesions.

    Peptide
    Melanotan II
    Outcome
    No significant changeSuppression of food intake by MTII
    Study

    ratn: not reported in source

    PVN-lesioned and sham-lesioned female Sprague-Dawley rats
    Comparator
    Sham-lesioned rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1 nmole or 1.0 nmoleAs given in this study (rat).

    Source sentences

    Summary
    Suppression of food intake in PVN-lesioned rats was not different from that in sham-lesioned rats.
    2 context sentences
    Summary · context
    Doses of 0.1 nmole or 1.0 nmole of MTII were injected immediately before lights-off and food intake was measured at 2 h, 24 h and 48 h post-injection.
    Summary · context
    Adult female Sprague-Dawley rats received either sham or electrolytic lesions in the PVN immediately followed by implantation of a guide cannula into the third cerebroventricle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.